Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 20, 2022 09:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201

NEBULIZED FORMULATION BEING DEVELOPED TO IMPROVE LUNG FUNCTION IN BOTH ACTIVE-DISEASE COVID-19 PATIENTS AND “LONG HAUL” PATIENTS WITH POST-INFECTION PULMONARY DISEASE SEATTLE, April 20, 2022 (GLOBE...